News
International NASH Day 2022 – Enabling therapies for patients
Non-alcoholic steatohepatitis, or NASH, remains a disease with no approved therapeutics. And it’s been a tough area for drug development, with numerous Phase 2b and
TherapeutAix to present at Extracellular Matrix Pharmacology Congress
TherapeutAix is attending and presenting at the Extracellular Matrix Pharmacology Congress 2022, on 23-25 June at the Tivoli Congress Centre in Copenhagen. The congress will
Workshops reloaded
At TherapeutAix, we have a number of tools to support our clients. In addition to, for example, the MIRIADD approach and our R&D network, we
Rare and common diseases – where’s the link?
It’s Rare Disease Day. Last year on our blog, we looked at how rare diseases can help better our understanding of common diseases. This year,
Adoption and cost-effectiveness of IPF therapies
Fibrotic remodelling occurs in many diseases. Thinking about idiopathic pulmonary fibrosis (IPF) as a ‘purely’ fibrotic condition, with currently unknown aetiology, may offer strategic insights
Happy Birthday TherapeutAix! Celebrating our third year
As TherapeutAix celebrates our three-year birthday this month, we thought it would be a great opportunity to take a look back at our achievements over
Reflections from ERS
Having joined a wide range of sessions at the virtual ERS meeting last week, we were keen to share some of our reflections. Despite the virtual format